Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12104/64866
Título: Fibrogenic polymorphisms (TGF-β, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment
Autor: Armendariz-Borunda, J.
Rincon, A.R.
Munoz-Valle, J.F.
Bueno-Topete, M.
Oregon-Romero, E.
Islas-Carbajal, M.C.
Medina-Preciado, D.
Gonzalez-Garcia, I.
Bautista, A.
Garcia-Rocha, S.
Godoy, J.
Mercado, M.V.-D.
Troyo-SanRoman, R.
Arellano-Olivera, I.
Lucano, S.
Alvarez-Rodriguez, A.
Salazar, A.
Fecha de publicación: 2008
Resumen: Background/Aim: The aim of this work was to establish a potential correlation between specific polymorphisms and presence of hepatic fibrosis in Mexican patients with established liver fibrosis (ELF). Second, necroinflammatory index improvement was correlated with Pirfenidone (PFD) treatment response and the same polymorphisms. Methods: We analyzed TGF-β polymorphisms in codon 25, a single basepair guanine insertion-deletion polymorphism (4G/5G) for PAI-1 and angiotensin AT-6 single nucleotide polymorphism located in -6 promoter region. Twenty patients infected with either hepatitis C virus (HCV) (n = 13) or affected by alcohol consumption (n = 7) were included. Thirty subjects with no hepatic damage were included in control group. Blood samples for genomic DNA were obtained and plasminogen activator inhibitor-1 polymorphisms were done by polymerase chain reaction-artificial introduction of a restriction site, TGF-β by polymerase chain reaction-amplification refractory mutation system and AT by polymerase chain reaction-restriction fragment length polymorphisms. Liver biopsies were obtained at baseline and after 12 months of PFD treatment. Results: Established liver fibrosis patients had the homo-zygote G/G TGF-β genotype, which has been associated with increased development of fibrosis. None of our patients had the G/C genotype. All pure HCV and pure alcohol abuse subjects carried G/G TGF-β genotype (100% vs 37% control) (P = 0.0006). The odds of having β G/G genotype was 19.5 for HCV patients and 10.83 for alcohol consumption patients as compared with healthy subjects (P < 0.001). Established liver fibrosis patients had an improvement in necroinflammatory index after PFD treatment when correlated with plasminogen activator inhibitor-1 and angiotensinogen-6 genotypes. Conclusion: Our data suggested that a combination of inherited polymorphisms increased the risk of advanced fibrosis in ELF patients. Pure HCV and pure alcohol consumption patients which were homozygous G/G carriers had 19.5- and 10.8-fold higher risk to develop advanced fibrosis respectively. © 2008 by The American Federation for Medical Research.
URI: http://hdl.handle.net/20.500.12104/64866
Aparece en las colecciones:Producción científica UdeG (prueba)

Ficheros en este ítem:
No hay ficheros asociados a este ítem.

Los ítems de RIUdeG están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.